Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

NIH launches drug trial for deadly cytokine storm

By Sean Whooley | October 16, 2020

The National Institutes of Health today launched a Phase 3 clinical trial to evaluate three immune modulator drugs in hospitalized adults with COVID-19.

Some COVID-19 patients experience an immune response in which the immune system unleashes proteins that trigger inflammation, otherwise known as a cytokine storm, which can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications, according to an NIH news release.

NIH’s trial is looking to find if modulating the immune response can reduce the need for ventilators and thus shorten hospital stays because the therapeutic has restored balance to an overactive immune system.

ACTIV-1 IM expects to enroll approximately 2,100 hospitalized adults with moderate to severe COVID-19 in the U.S. and Latin America. The randomized, placebo-controlled trial is set to use an adaptive master protocol to swiftly weed out drugs that aren’t effective and incorporate additional experimental therapeutics into the trial.

So far, the ACTIV public-private partnership selected three agents for the study from a pool of over 130, with infliximab from Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals, abatacept from Bristol-Myers Squibb (NYSE:BMY) and Cenicriviroc from AbbVie (NYSE:ABBV).

All trial participants will receive remdesivir, although the World Health Organization reported today that remdesivir has little to no effect in reducing coronavirus deaths. Convalescent plasma and dexamethasone will be allowed at the discretion of the site investigator and in accordance with the national guidelines. The patients will be randomly assigned to receive a placebo or one of the immune modulators as an add-on.

Enrollment is now open and the trial is expected to last for approximately six months, with results set to be made available shortly after the trial is completed, or possibly sooner if early data indicates that one or more of the drugs is beneficial.

“This is the fifth master protocol to be launched under the ACTIV partnership in an unprecedented timeframe, and focuses efforts on therapies that hold the greatest promise for treating COVID-19,” NIH Director Dr. Francis S. Collins said in the release. “Immune modulators provide another treatment modality in the ACTIV therapeutic toolkit to help manage the complex, multi-system conditions that can be caused by this very serious disease.”


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: AbbVie, Bristol-Myers Squibb, coronavirus, covid-19, Janssen Pharmaceutical Cos., Johnson & Johnson, National Institutes of Health
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE